Similarly, the development of resistance to BRAF inhibitors in melanoma has been shown to be linked to the upregulation of Notch signaling, while inhibiting this signaling pathway resensitized the cancer to the targeted therapy [64,65,66,67]. This evidence concerns the gene BRAF and cancer.